XMP0 Stock Overview
A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Plus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.13 |
| 52 Week High | US$2.42 |
| 52 Week Low | US$0.94 |
| Beta | 0.67 |
| 11 Month Change | -14.13% |
| 3 Month Change | -17.16% |
| 1 Year Change | -1.40% |
| 33 Year Change | -94.97% |
| 5 Year Change | -96.58% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| XMP0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -14.9% | 0.2% | -1.0% |
| 1Y | -1.4% | -9.9% | 12.8% |
Return vs Industry: XMP0 exceeded the German Biotechs industry which returned -9.9% over the past year.
Return vs Market: XMP0 underperformed the German Market which returned 12.8% over the past year.
Price Volatility
| XMP0 volatility | |
|---|---|
| XMP0 Average Weekly Movement | 15.9% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XMP0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XMP0's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 20 | Marc Hedrick | plustherapeutics.com |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection.
Plus Therapeutics, Inc. Fundamentals Summary
| XMP0 fundamental statistics | |
|---|---|
| Market cap | €7.00m |
| Earnings (TTM) | -€12.05m |
| Revenue (TTM) | €5.02m |
1.4x
P/S Ratio-0.6x
P/E RatioIs XMP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XMP0 income statement (TTM) | |
|---|---|
| Revenue | US$5.51m |
| Cost of Revenue | US$10.82m |
| Gross Profit | -US$5.31m |
| Other Expenses | US$7.92m |
| Earnings | -US$13.23m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.24 |
| Gross Margin | -96.46% |
| Net Profit Margin | -240.15% |
| Debt/Equity Ratio | -43.2% |
How did XMP0 perform over the long term?
See historical performance and comparison